Abstract 5280
Background
With increasing emphasis on health-related quality of life (HRQoL), EuropaColon, a European CRC patient organization, conducted a European survey on experience and HRQoL in mCRC in 12 countries. The aim is to report the interim results with the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) for Hungary (HU), Poland (PL), Serbia (RS) and Spain (ES).
Methods
After IRB approval, clinicians, nurses with partner organizations of EuropaColon recruited patients. In addition to demographics, diagnosis and treatment (reported elsewhere), the survey assessed HRQoL using EORTC QLQ-C30. Single data entry was done by EuropaColon. The QLQ-C30 global score, function- and symptom-specific scores, and the financial difficulties item were summarized by country using the “QoLR” package in R .
Results
548 surveys were analyzed. Completion rates were high in RS, PL and HU (>95%), and lower in ES (77-79%). Place in treatment pathway varied (e.g. in HU 92.2% were undergoing, while in RS 25.6% completed treatment). Scores were consistently higher in HU and ES, with emotional function affected the most.Table: 574P
| Country | Mean score (SD) | |||||
|---|---|---|---|---|---|---|
| Global Quality of Life | Functions | |||||
| Physical | Role | Emotional | Cognitive | Social | ||
| HU | 69.4 (20.7) | 82.9 (16.3) | 81.4 (23.7) | 73.9 (22.5) | 87.9 (19.1) | 80.9 (24.6) |
| PL | 56.1 (18.1) | 70.1 (20.5) | 71.9 (28.2) | 67.1 (22.7) | 76.7 (22.3) | 67.2 (27.5) |
| RS | 55.9 (21.1) | 69.7 (19.5) | 63.6 (25.7) | 53.5 (28.4) | 71.3 (24.6) | 53.9 (26) |
| ES | 68.1 (21.6) | 84.3 (17.9) | 81.8 (25.4) | 76.4 (24.1) | 85.4 (19.4) | 77.7 (24.1) |
Mean fatigue and pain symptom scores were lower in HU/ES and higher in RS/PL. This was maintained in nausea, insomnia, appetite loss, constipation, but not in dyspnea, diarrhea. Differences could be affected by the patients’ place in the treatment pathway. Global health scores for RS and PL were lower, and symptom scores were higher than reported in mCRC trials.
Conclusions
mCRC has an important effect on HRQoL, which can differ among real-world mCRC patients and those in clinical trials. Variations across countries and comparisons to HRQoL in trials require further analysis.
Clinical trial identification
Legal entity responsible for the study
EuropaColon.
Funding
Merck, BMS, Sandoz, Sirtex.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.